<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704218</url>
  </required_header>
  <id_info>
    <org_study_id>2022/736</org_study_id>
    <nct_id>NCT05704218</nct_id>
  </id_info>
  <brief_title>Hypersensitivity Pneumonitis of Domestic Origin</brief_title>
  <acronym>HOME-HP</acronym>
  <official_title>Hypersensitivity Pneumonitis of Domestic Origin: Investigation of the Microorganisms Involved and Improvement of Serological Diagnosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exposure to molds in dwellings is a public health problem. Diagnosis of hypersensitivity&#xD;
      pneumonitis due to mold exposure at home (domestic HP) are increasing. To perform the&#xD;
      serodiagnosis of domestic HP a cohort constitued of proven cases and exposed healthy controls&#xD;
      are needed.&#xD;
&#xD;
      The HOME HP study aimed at obtaining a cohort of proven cases and exposed controls in order&#xD;
      to be able to improve the serodiagnosis of domestic HP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypersensitivy pneumonitis (HP) are chronic respiratory diseases due to frequent exposure to&#xD;
      high quantities of allergens (molds, bacteria, mycobacteria, avian proteins). In case of&#xD;
      domestic HP, patients are exposed at home to molds due to flooding or poor ventilation.&#xD;
&#xD;
      The diagnosis of domestic HP includes detection of IgG towards molds. A prior study in 2005&#xD;
      allowed the determination of frequent allergenic molds isolated in homes in Bourgogne Franche&#xD;
      Comte (study on 110 dwellings). However, no real cohort of proven cases versus controls is&#xD;
      available. So, we are lacking validated thresholds. The HOME HP study is a prospective study&#xD;
      that will include several centers of pneumology on France territory. The fungal contamination&#xD;
      of dwellings occupied by patients suffering of interstitial disease (DIP), including&#xD;
      suspicion of domestic HP, will be analyzed. The most frequently isolated molds will be then&#xD;
      produced as antigens and will be tested in order to assess the sensitization of the included&#xD;
      patients. The data of imagery, BALF cytology will allow to determine if patients are&#xD;
      diagnosed with domestic HP or not. We will then obtain 2 groups of patients 1-proven domestic&#xD;
      HP and 2-non domestic HP . Comparing the number of immunization arcs between the 2 groups&#xD;
      will then be possible to validate appropriate thresholds for the serodiagnosis of domestic&#xD;
      HP.&#xD;
&#xD;
      Domestic HP are rare diseases, so a high number of inclusions will be needed to obatin in 2&#xD;
      years about 25-30 proven cases. The HOME HP study is important to improve the serodiagnosis&#xD;
      of domestic HP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>the final diagnosis will be judged by the pneumologist on plural results: imagery, BALF cytology. The final diagnosis will be used to make 2 groups proven / non proven domestic forms</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of mold sensitisation</measure>
    <time_frame>2 years</time_frame>
    <description>serology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of mold presence in dwellings</measure>
    <time_frame>2 years</time_frame>
    <description>dust collectors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>testing of new fungal antigens</measure>
    <time_frame>2 years</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Sensitisation</condition>
  <condition>Mold or Dust Allergy</condition>
  <condition>Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>domestic HP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All the patients will be in the same arm until obtention of the final diagnosis.&#xD;
The final diagnosis will be used to compare data of serology to determine thresholds</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>the patient will have a blood sample in order to perform serology tests</description>
    <arm_group_label>domestic HP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  exposure to mold at home&#xD;
&#xD;
          -  given consent&#xD;
&#xD;
          -  suspicion of doemstic HP&#xD;
&#xD;
          -  clinical signs of interstial pneumopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunocompromised patients&#xD;
&#xD;
          -  prior diagnosis of another HP form (avian, farm, bath tub etc..)&#xD;
&#xD;
          -  exposure to avian proteins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Pauline BELLANGER</last_name>
    <phone>0370632351</phone>
    <email>apbellanger@chu-besancon.fr</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>December 2, 2022</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypersensitivity pneumonitis</keyword>
  <keyword>molds</keyword>
  <keyword>dwellings</keyword>
  <keyword>thresholds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

